AutoGenomics Receives a Key European Patent for HPV Detection
CARLSBAD, Calif., June 18 /PRNewswire/ — AutoGenomics, a leader in providing automated, molecular testing solutions, announced today that it has been issued a key European patent for Human papillomavirus. Patent No.1 499 749 B1, “Human papillomavirus Detection with DNA Microarray,” claims to be a method for detecting the presence of HPV using a microarray.
“This patent is the result of our collaboration with Dr. Erik Thunnissen, a prominent clinician and opinion leader in the field of Human papillomavirus,” said Mr. Fareed Kureshy, President and CEO of AutoGenomics. He further said that “with increasing demands for alternative technologies to meet the evolving need for genotyping we are excited that we can offer an automated solution that can significantly enhance workflow efficiency in the laboratory”.
AutoGenomics Inc., a privately held company based in Carlsbad, CA., has developed the first automated, microarray based multiplexing diagnostic platform that can be used to assess disease signatures with novel genomic and proteomic markers in the area of genetic disorders, infectious disease, cancer and pharmacogenetics. With the discovery of genes and their link to various disease states the platform has the versatility to revolutionize the way patients are diagnosed, monitored and managed, leading to the era of personalized medicine. http://www.autogenomics.com/
CONTACT: Ramanath Vairavan, President Sales & Marketing of AutoGenomicsInc., +1-760-804-7378 x 305, firstname.lastname@example.org
Web site: http://www.autogenomics.com/